Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.62 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.62 |
| ▸ | KCNK18 | Q7Z418 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6141831 | 0.80 | FABP4 (0.35) | MEN1KMT2AKCNK2KCNK10KCNK18 | |
| SCHEMBL29389546 | 0.77 | KCNK2 (1.00) | MEN1KMT2AKCNK2KCNK10KCNK18 | |
| SCHEMBL23094057 | 0.76 | MEN1 (0.40) | MEN1KMT2AKCNK2KCNK10KCNK18 | |
| SCHEMBL12101466 | 0.75 | MEN1 (0.56) | MEN1KMT2AKCNK2KCNK10KCNK18 | |
| SCHEMBL21359827 | 0.74 | MEN1 (0.38) | MEN1KMT2AKCNK2KCNK10KCNK18 | |
| SCHEMBL4455889 | 0.70 | — | — | |
| SCHEMBL8505056 | 0.70 | ACHE (0.39) | MEN1KMT2ATDP1SMN1; SMN2NPSR1 | |
| SCHEMBL5680255 | 0.69 | IDO1 (0.40) | MEN1KMT2AKCNK2KCNK10KCNK18 | |
| SCHEMBL3476601 | 0.68 | MEN1 (0.51) | MEN1KMT2AKCNK2KCNK10KCNK18 | |
| SCHEMBL12615990 | 0.68 | ALDH1A1 (0.38) | MEN1KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862684-B2 | Modulation of K2P channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| EP-2968270-A2 | MODULATION OF K2P CHANNELS | The Regents of The University of California (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014165307-A9 | MODULATION OF K2P CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | WO | disclosed |
| WO-2014165307-A2 | MODULATION OF K2P CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8097650-B2 | Method of treating a condition associated with phosphorylation of TASK-1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097650-B2 | Method of treating a condition associated with phosphorylation of TASK-1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097650-B2 | Method of treating a condition associated with phosphorylation of TASK-1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2068628-A2 | METHOD OF TREATING A CONDITION ASSOCIATED WITH PHOSPHORYLATION OF TASK-1 | The Trustees of Columbia University in the City of New York (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008013988-A9 | METHOD OF TREATING A CONDITION ASSOCIATED WITH PHOSPHORYLATION OF TASK-1 | UNIV COLUMBIA (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20070259051-A1 | Method of treating a condition associated with phosphorylation of TASK-1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-11-08 | — | — | US | disclosed |
| US-20070259051-A1 | Method of treating a condition associated with phosphorylation of TASK-1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-11-08 | — | — | US | disclosed |
| US-20070259051-A1 | Method of treating a condition associated with phosphorylation of TASK-1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-11-08 | — | — | US | disclosed |
| WO-2007014347-A9 | METHOD OF TREATING A CONDITION ASSOCIATED WITH PHOSPHORYLATION OF TASK-1 | UNIV COLUMBIA (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007014347-A9 | METHOD OF TREATING A CONDITION ASSOCIATED WITH PHOSPHORYLATION OF TASK-1 | UNIV COLUMBIA (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070082374-A1 | Method of treating a condition associated with phosphorylation of task-1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-12 | — | — | US | disclosed |
| US-20070082374-A1 | Method of treating a condition associated with phosphorylation of task-1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-12 | — | — | US | disclosed |
| US-20070082374-A1 | Method of treating a condition associated with phosphorylation of task-1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-12 | — | — | US | disclosed |
| WO-2007014347-A2 | METHOD OF TREATING A CONDITION ASSOCIATED WITH PHOSPHORYLATION OF TASK-1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007014347-A2 | METHOD OF TREATING A CONDITION ASSOCIATED WITH PHOSPHORYLATION OF TASK-1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082374-A1 | Method of treating a condition associated with phosphorylation of task-1 | TTBK1, PEAK1, TLK1 | MEN1 1967/4885KMT2A 1401/4885KCNK2 437/4885 |
| US-20070259051-A1 | Method of treating a condition associated with phosphorylation of TASK-1 | TTBK1, PEAK1, TLK1 | MEN1 1967/4885KMT2A 1401/4885KCNK2 437/4885 |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | KCNJ2, KCNK2, KCNN3 | MEN1 4246/4885KMT2A 449/4885KCNK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.